<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BENAZEPRIL HYDROCHLORIDE</span><br/>(ben-a'ze-pril)<br/><span class="topboxtradename">Lotensin<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme (ace) inhibitor</span><br/><b>Prototype: </b>Enalapril<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Lowers blood pressure by specific inhibition of the angiotensin-converting enzyme (ACE) and thus by decreasing angiotensin
         II (a potent vasoconstrictor) and aldosterone secretion.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Benazepril achieves an antihypertensive effect by suppression of the renin-angiotensin-aldosterone system.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of mild to moderate hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF, reno-protective agent.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to benazepril or another ACE inhibitor. Safety during pregnancy (category D), lactation, or in children is
         not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal impairment, renal-artery stenosis; patients with hypovolemia, receiving diuretics, undergoing dialysis; patients in
         whom excessive hypotension would present a hazard (e.g., cerebrovascular insufficiency); CHF; hepatic impairment; diabetes
         mellitus.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1040 mg/d in 12 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Consult physician about initial dose if patient is also receiving diuretics. Typically an initial dose of 5 mg is used to
            minimize the risk of hypotension.
         </li>
<li>Store at room temperature, but not above 30° C (86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Hypotension. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness, fatigue, weakness. <span class="typehead">Endocrine:</span> Hyperkalemia (at higher doses). <span class="typehead">GI:</span> Nausea, diarrhea or constipation, gastritis. <span class="typehead">Urogenital:</span> Azotemia, oliguria, renal failure in patients with CHF. <span class="typehead">Respiratory:</span> Cough, rhinitis, bronchitis. <span class="typehead">Other:</span> Back pain. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Elevations in <span class="alt">serum bilirubin</span> have been observed after benazepril administration. Benazepril inhibits <span class="alt">aldosterone</span> secretion, which causes an increase in <span class="alt">serum potassium.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">potassium-sparing diuretics</span> may increase the risk of hyperkalemia. Benazepril may increase <b>lithium</b> levels, resulting in <b>lithium</b> toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract with 37% reaching the systemic circulation. <span class="typehead">Peak:</span> 26 h. <span class="typehead">Duration:</span> 2024 h. <span class="typehead">Distribution:</span> Small amounts cross the blood-brain barrier; crosses placenta; small amount excreted in breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite, benazeprilat. <span class="typehead">Elimination:</span> Benazeprilat (product of drug) is primarily excreted in urine. <span class="typehead">Half-Life:</span> Benazepril 0.6 h; benazeprilat 22 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for hypotension, especially in patients who may be volume depleted (e.g., prolonged diuretic therapy, recent vomiting
            or diarrhea, salt restriction) or who have CHF.
         </li>
<li>Lab tests: Monitor serum potassium levels for hyperkalemia (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use salt substitutes unless recommended by physician.</li>
<li>Report swelling of face, eyes, lips, or tongue or difficulty breathing immediately to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>